LAVA Therapeutics (LVTX) Price & Analysis

Compare

165 Followers

LVTX Stock Chart & Stats

$1.61

-$0.03(-2.78%)

At close: Jan 08 4:00 PM EST

$1.61

-$0.03(-2.78%)

Day’s Range― - ―

52-Week Range$0.85 - $2.09

Previous CloseN/A

Volume31.56K

Average Volume (3M)430.90K

Market Cap

$38.93M

Enterprise Value-$20.66M

Total Cash (Recent Filing)$56.17M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.39

Next Earnings

Nov 12, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding26,305,296

10 Day Avg. Volume419,635

30 Day Avg. Volume430,902

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.53

Enterprise Value/Revenue-4.14

Enterprise Value/Gross Profit1.04

Enterprise Value/Ebitda0.80

Forecast

1Y Price Target

$1.37

Price Target Upside-14.91% Downside

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

AcquisitionXOMA to acquire LAVA in cash-and-CVR deal, offering a definitive agreement for shareholders.

Clinical ProgressProgress continues with LAVA-1266, a Gammabody targeting CD123 for acute myeloid leukemia and myelodysplastic syndrome.

Financial PerformanceThe company reported license revenue of $5M and a net loss of $0.14 per share, better than the consensus estimate of revenue of $2.5M and a net loss of 0.30 per share.

Bears Say

Clinical ChallengesThe company's sole remaining wholly-owned clinical asset, LAVA-1266, lacks supportive clinical data.

Earnings ReportFor 1Q25, the company reported no revenue and a net loss of $0.13 per share.

Workforce ReductionIn February, the company announced a workforce reduction of approximately 30% and initiated a strategic review.

LAVA Therapeutics News

Xoma, Lava Therapeutics announce amendment to purchase agreement

XOMA Royalty Corporation (XOMA) and LAVA Therapeutics N.V. (LVTX) announced that they have reached an agreement to amend...

7d ago

LVTX

XOMA

Xoma extends offer to acquire Lava Therapeutics

Xoma (XOMA) and Lava Therapeutics (LVTX) announced the extension of the expiration of the tender offer to purchase...

22d ago

LVTX

XOMA

Lava Therapeutics to move Extraordinary General Meeting to early November

LAVA Therapeutics (LVTX) has decided to cancel the Extraordinary General Meeting of Shareholders scheduled to occur on September...

24d ago

LVTX

XOMA

LAVA Therapeutics Amends Share Purchase Agreement

LAVA Therapeutics ( ($LVTX) ) has provided an announcement. On October 17, 2025, LAVA Therapeutics N.V. and XOMA...

7d ago

LVTX

LAVA Therapeutics Extends Tender Offer Deadline

The latest announcement is out from LAVA Therapeutics ( ($LVTX) ). On October 2, 2025, LAVA Therapeutics and...

22d ago

LVTX

LAVA Therapeutics Postpones EGM for XOMA Deal

LAVA Therapeutics ( ($LVTX) ) has provided an announcement. On September 30, 2025, LAVA Therapeutics announced the cancellation...

24d ago

LVTX

Lava Therapeutics Reports Q2 2025 Financial Results

Lava Therapeutics Nv ( ($LVTX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

LVTX

LAVA Therapeutics Announces Acquisition by XOMA Corporation

LAVA Therapeutics ( ($LVTX) ) has issued an announcement. On August 13, 2025, LAVA Therapeutics announced its acquisition...

2M ago

LVTX

Lava Therapeutics reports Q2 EPS (32c) vs. (31c) last year

Reports Q2 revenue $0 vs. $0 last year. As of June 30, Lava had cash, cash equivalents, and...

2M ago

LVTX

Hold Rating on XOMA’s Acquisition of LAVA Therapeutics: Valuation and Risks Assessed

Analyst Arthur He CFA from H.C. Wainwright reiterated a Hold rating on LAVA Therapeutics and decreased the price...

3M ago

LVTX

Lava Therapeutics downgraded to Hold from Buy at Jefferies

Jefferies downgraded Lava Therapeutics (LVTX) to Hold from Buy with a price target of $1.50, down from $3,...

3M ago

LVTX

LAVA Therapeutics Agrees to Acquisition by XOMA

The latest announcement is out from LAVA Therapeutics ( ($LVTX) ). On August 3, 2025, LAVA Therapeutics entered...

3M ago

LVTX

Xoma to acquire Lava Therapeutics for $1.16-$1.24 per share in cash plus CVR

XOMA Royalty (XOMA) and LAVA Therapeutics (LVTX) entered a definitive share purchase agreement whereby XOMA Royalty will acquire...

3M ago

LVTX

XOMA

Lava Therapeutics’ LAVA-1207 Study Terminated: Implications for Investors

Lava Therapeutics Nv (($LVTX)) announced an update on their ongoing clinical study. Study Overview: Lava Therapeutics Nv recently...

3M ago

LVTX

LVTX FAQ

What was LAVA Therapeutics’s price range in the past 12 months?

LAVA Therapeutics lowest stock price was $0.85 and its highest was $2.09 in the past 12 months.

What is LAVA Therapeutics’s market cap?

LAVA Therapeutics’s market cap is $38.93M.

When is LAVA Therapeutics’s upcoming earnings report date?

LAVA Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 19 days.

How were LAVA Therapeutics’s earnings last quarter?

LAVA Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.257 by -$0.063.

Is LAVA Therapeutics overvalued?

According to Wall Street analysts LAVA Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does LAVA Therapeutics pay dividends?

LAVA Therapeutics does not currently pay dividends.

What is LAVA Therapeutics’s EPS estimate?

LAVA Therapeutics’s EPS estimate is -0.25.

How many shares outstanding does LAVA Therapeutics have?

LAVA Therapeutics has 26,305,296 shares outstanding.

What happened to LAVA Therapeutics’s price movement after its last earnings report?

LAVA Therapeutics reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.257. Following the earnings report the stock price went up 0.654%.

Which hedge fund is a major shareholder of LAVA Therapeutics?

Currently, no hedge funds are holding shares in LVTX

LAVA Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-90.07%

Trailing 12-Months

Asset Growth

-34.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

LAVA Therapeutics

LAVA Therapeutics (LVTX) is a biotechnology company focused on developing innovative treatments for cancer through its proprietary Gammabody platform, which leverages the unique properties of gamma delta T cells. The company specializes in advancing bispecific antibody therapies designed to enhance the immune system's ability to target and destroy cancer cells. LAVA operates primarily in the biopharmaceutical sector, concentrating on oncology and immunotherapy.

LAVA Therapeutics (LVTX) Earnings & Revenues

Historic Earnings Reports

LVTX Stock 12 Month Forecast

Average Price Target

$1.37

▼(-14.91% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,1.5553846153846154,1.550769230769231,1.5461538461538462,1.5415384615384615,1.536923076923077,1.5323076923076924,1.5276923076923077,1.523076923076923,1.5184615384615385,1.5138461538461538,1.5092307692307692,1.5046153846153847,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,1.5453846153846154,1.5307692307692309,1.5161538461538462,1.5015384615384617,1.486923076923077,1.4723076923076923,1.4576923076923078,1.4430769230769231,1.4284615384615384,1.413846153846154,1.3992307692307693,1.3846153846153848,{"y":1.37,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,1.5353846153846153,1.5107692307692309,1.4861538461538462,1.4615384615384617,1.436923076923077,1.4123076923076923,1.3876923076923078,1.363076923076923,1.3384615384615386,1.3138461538461539,1.2892307692307692,1.2646153846153847,{"y":1.24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.2,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >